QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
NASDAQ:OABI

OmniAb (OABI) Stock Price, News & Analysis

$5.84
-0.37 (-5.96%)
(As of 02/29/2024 ET)
Today's Range
$5.84
$6.36
50-Day Range
$5.28
$6.69
52-Week Range
$3.14
$6.72
Volume
993,281 shs
Average Volume
411,268 shs
Market Capitalization
$678.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.75

OmniAb MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
49.8% Upside
$8.75 Price Target
Short Interest
Bearish
5.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.66mentions of OmniAb in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.53) to ($0.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.46 out of 5 stars

Medical Sector

765th out of 958 stocks

Commercial Physical Research Industry

11th out of 13 stocks


OABI stock logo

About OmniAb Stock (NASDAQ:OABI)

OmniAb, Inc., a biotechnology company, engages in the provision of therapeutic antibody discovery technologies in the United States. The company's discovery platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTau, which features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

OABI Stock Price History

OABI Stock News Headlines

2 Speculative Small-Cap Biotech Stocks You Should Know About
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
OmniAb to Participate in Two Investor Conferences in March
OmniAb Inc OABI
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
OmniAb (OABI) Receives a Buy from RBC Capital
OmniAb, Inc. (OABIW)
President of OmniAb Matthew Foehr Buys 8.2% More Shares
OmniAb files for $300M mixed shelf
Matthew Foehr Bought 4.1% More Shares In OmniAb
See More Headlines
Receive OABI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OmniAb and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
2/29/2024
Next Earnings (Confirmed)
3/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:OABI
Fax
N/A
Employees
95
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.75
High Stock Price Target
$11.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+49.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-22,330,000.00
Pretax Margin
-53.64%

Debt

Sales & Book Value

Annual Sales
$59.08 million
Book Value
$2.96 per share

Miscellaneous

Free Float
108,101,000
Market Cap
$678.84 million
Optionable
Optionable
Beta
-0.18
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Matthew W. Foehr (Age 51)
    President, CEO & Director
    Comp: $967.72k
  • Mr. Kurt A. Gustafson (Age 56)
    Executive VP of Finance & CFO
    Comp: $558.48k
  • Mr. Charles S. Berkman J.D. (Age 55)
    Chief Legal Officer & Secretary
    Comp: $734.33k
  • Ms. Cia McCaffrey
    Vice President of People & Talent
  • Dr. Bill Harriman Ph.D.
    Senior Vice President of Antibody Discovery
  • Ms. Marie-Cecile van de Lavoir D.V.M.
    Ph.D., Senior Vice President of Technical Operations & Genetics
  • Dr. Christel Iffland Ph.D.
    Senior Vice President of Antibody Technologies
  • Dr. Douglas S. Krafte Ph.D. (Age 66)
    Senior VP of Ion Channels/Transporters & Icagen Ion Channel Technology Site Head
  • Ms. Donna Ventura CPA
    Senior Vice President of Corporate Controller














OABI Stock Analysis - Frequently Asked Questions

Should I buy or sell OmniAb stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OmniAb in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OABI shares.
View OABI analyst ratings
or view top-rated stocks.

What is OmniAb's stock price target for 2024?

4 equities research analysts have issued 12 month price targets for OmniAb's shares. Their OABI share price targets range from $6.00 to $11.00. On average, they anticipate the company's stock price to reach $8.75 in the next year. This suggests a possible upside of 49.8% from the stock's current price.
View analysts price targets for OABI
or view top-rated stocks among Wall Street analysts.

How have OABI shares performed in 2024?

OmniAb's stock was trading at $6.17 at the beginning of 2024. Since then, OABI shares have decreased by 5.3% and is now trading at $5.84.
View the best growth stocks for 2024 here
.

When is OmniAb's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our OABI earnings forecast
.

How can I listen to OmniAb's earnings call?

OmniAb will be holding an earnings conference call on Wednesday, March 20th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Who are OmniAb's major shareholders?

OmniAb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.86%), Private Management Group Inc. (2.27%), Dimensional Fund Advisors LP (2.26%), Villere ST Denis J & Co. LLC (1.85%), Orchard Capital Management LLC (1.17%) and Kornitzer Capital Management Inc. KS (1.05%). Insiders that own company stock include Jennifer R Cochran, John L Higgins, Kurt A Gustafson and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of OmniAb?

Shares of OABI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OABI) was last updated on 2/29/2024 by MarketBeat.com Staff